查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933311

黏多醣貯積症治療市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察，預測（2026-2034 年）

Mucopolysaccharidosis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

黏多醣貯積症 (MPS) 治療市場成長驅動因子

預計未來十年，全球黏多醣貯積症 (MPS) 治療市場將迎來顯著成長。該市場預計在 2025 年達到 39.6 億美元，2026 年成長至 43.7 億美元，並在 2034 年達到 97.4 億美元。這意味著 2026 年至 2034 年的複合年增長率 (CAGR) 為 10.54%。北美地區在 2025 年將佔市場主導地位，市佔率達到 52.10%，主要得益於較高的診斷率、活躍的臨床試驗以及有利的報銷政策。

代謝性多醣症候群 (MPS) 是一組罕見的代謝性疾病，由溶酶體酶缺乏引起，促使細胞內糖胺聚醣 (GAG) 異常積累。這會促使嚴重的症狀，包括神經系統併發症、器官功能障礙和生長異常。對先進療法的需求不斷增長以及未被滿足的醫療需求正在推動全球市場成長。

市場驅動因素

MPS 治療市場的主要驅動因素是未被滿足的醫療需求以及對先進療法以改善治療效果的需求。目前的治療方法，例如用於治療亨特氏症候群的酵素替代療法 (ERT)，如 Elaprase 和用於治療莫爾基奧症候群的 Vimizim（elosulfase alfa），通常價格昂貴，限制了發展中國家的用藥。此外，現有療法無法穿過血腦屏障，促使神經系統症狀在很大程度上無法治療。

Almagen、Regenx Bio 和 Denali Therapeutics 等生物製藥公司正在加強研發力度，致力於開發包括基因療法和造血幹細胞移植 (HSCT) 在內的先進療法，以應對 MPS 的所有症狀。預計這項研發管線的擴展將在預測期內推動市場成長。

市場限制因子

高昂的治療費用、較低的診斷率以及新興國家有限的醫療資源是限制市場發展的因素。酵素替代療法 (ERT) 的費用極為昂貴，每年的治療費用超過 100 萬日元，令許多患者難以負擔。診斷延遲、認知不足以及缺乏完善的政府報銷體系進一步阻礙了發展中地區的市場擴張。

市場趨勢

一個重要的趨勢是，人們越來越關注罕見疾病和孤兒病的治療。 作為一種罕見疾病，MPS 吸引了許多生物製藥公司的關注，他們致力於為特定市場開發重磅療法。針對多種 MPS 亞型的臨床試驗數量正在增加，反映出對罕見疾病藥物研發的投資不斷增長。

此外，基因療法和幹細胞療法的進展標誌著治療方向正從傳統的酵素替代療法 (ERT) 轉向潛在的治癒性療法，這提升了市場對投資者和醫療保健提供者的吸引力。

市場區隔分析

依療法分類：

  • 由於酵素替代療法 (ERT) 在治療溶小體貯積症方面已證實有效，預計到 2026 年，ERT 將佔市場主導地位，市場佔有率將達到 93.89%。
  • 隨著更多在研藥物進入臨床試驗階段，預計基因療法和造血幹細胞移植 (HSCT) 等其他療法在預測期內將以較高的複合年增長率增長。

依疾病類型劃分：

  • MPS II（亨特氏症候群）預計將在2026年保持其領先地位，市佔率為24.25%，主要得益於Elaprase和Hunterase等關鍵產品的推動。
  • 其他類型，例如MPS I、IV A、VI和VII（斯萊氏症候群），預計將穩定成長，這得益於MEPSEVII（貝斯曲尼酶α-vjbk）等新核准療法的支持。

依給藥途徑劃分：

  • 預計到2026年，靜脈（IV）給藥將佔主導地位，佔總收入的98.16%，因為包括Elaprase在內的大多數核准療法都是透過靜脈給藥的。
  • 腦室內（ICV）給藥目前應用有限，但得益於Hunterase等產品的出現，其應用正逐漸增加。

依最終使用者劃分：

  • 醫院將引領市場，到 2026 年將佔 61.55% 的市場。這是因為需要訓練有素的專業人員安全地進行靜脈輸液治療。
  • 在已開發地區，受病患對專業照護需求的推動，專科診所和其他醫療機構正在擴張。

區域分析

北美：2025 年市場規模估計為 20.6 億美元，預計到 2026 年將達到 21.3 億美元，這主要得益於較高的認知度、醫保報銷以及臨床試驗的開展。

歐洲：作為第二大市場，在積極的產品研發推動下，預計將以9.9%的複合年增長率成長，到2026年，英國市場規模將達到1.8億美元，德國將達到2.7億美元。

亞太地區：由於龐大的患者群體和即將上市的新藥，該地區預計將實現最快成長。預計日本市場規模將在2025年達到3.339億美元，2026年達到3.7億美元。中國市場規模預計將在2026年達到2.7億美元，印度市場規模將達1.3億美元。

世界其他地區：拉丁美洲和中東/非洲是新興市場，受益於不斷擴大的醫療基礎設施和政府主導的各項措施。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇

第四章：關鍵考慮因素

  • 各地區主要黏多醣貯積症類型盛行率（2025 年）
  • 在開發產品分析
  • 主要行業趨勢
  • 各地區監理環境
  • 黏多醣貯積症新興療法概述
  • 各地區健保報銷狀況

第五章：全球黏多醣貯積症治療市場

分析、洞察與預測，2021-2034
  • 主要發現/摘要
  • 依療法劃分的市場分析、洞見與預測
    • 酵素替代療法 (ERT)
    • 其他
  • 依疾病類型劃分的市場分析、洞察與預測
    • I型黏多醣貯積症
    • II型黏多醣貯積症
    • IVA型黏多醣貯積症
    • VI型黏多醣貯積症
    • 其他
  • 依給藥途徑劃分的市場分析、洞察與預測
    • 靜脈給藥
    • 腦室內給藥 (ICV)
  • 依最終用戶劃分的市場分析、洞察與預測
    • 醫院
    • 專科診所
    • 其他
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 世界其他地區

第六章：北美黏多醣貯積症治療市場分析、洞察與預測，2021-2034

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲黏多醣貯積症治療市場分析、洞察與預測，2021-2034

  • 依國家劃分
    • 美國王國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區

第八章 亞太地區黏多醣貯積症治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 韓國
    • 亞太其他地區

第九章：世界其他地區黏多醣貯積症治療市場分析、洞察與預測（2021-2034）

第十章：競爭分析

  • 主要行業趨勢
  • 全球市佔率分析（2017）
  • 競爭格局概覽
  • 主要公司競爭分析
  • 公司簡介
  • Shire(Takeda Pharmaceutical Company Limited)
  • Denali Therapeutics
  • ArmaGen
  • REGENXBIO Inc.
  • Sangamo Therapeutics
  • BioMarin
  • Lysogene
  • Abeona Therapeutics Inc.
  • Ultragenyx Pharmaceutical
  • Genzyme Corporation

第十一章 競爭分析

Product Code: FBI102551

Growth Factors of mucopolysaccharidosis (MPS) treatment Market

The global mucopolysaccharidosis (MPS) treatment market is projected to witness significant growth over the coming decade. In 2025, the market was valued at USD 3.96 billion, expected to grow to USD 4.37 billion in 2026 and reach USD 9.74 billion by 2034, reflecting a CAGR of 10.54% from 2026-2034. North America dominated the market with a 52.10% share in 2025, primarily driven by high diagnosis rates, strong clinical trial activity, and favorable reimbursement policies.

MPS is a group of rare metabolic disorders caused by deficiencies in lysosomal enzymes, leading to abnormal accumulation of glycosaminoglycans (GAGs) in cells. This results in severe symptoms, including neurological complications, organ dysfunction, and growth abnormalities. The growing need for advanced therapeutics and unmet clinical needs has propelled market growth globally.

Market Drivers

The MPS treatment market is primarily driven by the need for advanced therapeutics due to unmet clinical needs and better treatment outcomes. Current treatments, such as enzyme replacement therapies (ERTs) like Elaprase for Hunter syndrome and Vimizim (elosulfase alfa) for Morquio syndrome, are often prohibitively expensive, limiting access in developing countries. Additionally, existing therapies cannot cross the blood-brain barrier, leaving neurological symptoms largely untreated.

Increasing R&D initiatives by biopharmaceutical companies like ArmaGen, REGENXBIO, and Denali Therapeutics are focusing on developing advanced therapies, including gene therapies and hematopoietic stem cell transplantation (HSCT), to address the full spectrum of MPS symptoms. This pipeline expansion is expected to drive market growth during the forecast period.

Market Restraints

The market faces restraints due to high therapeutic costs, poor diagnosis rates, and limited access in emerging countries. ERTs are extremely expensive, with annual treatment costs reaching six figures, making them unaffordable for many patients. Diagnostic delays, lack of awareness, and insufficient government reimbursement further restrict market expansion in developing regions.

Market Trends

A key trend is the increasing focus on rare and orphan disease therapies. MPS, as an orphan disorder, attracts significant attention from biopharmaceutical companies aiming to develop blockbuster treatments in niche markets. Clinical trials for multiple MPS types are increasing, reflecting growing investment in rare disease drug development.

Additionally, advancements in gene therapy and stem cell treatments represent a shift from conventional ERTs toward potentially curative therapies, increasing the attractiveness of the market to investors and healthcare providers.

Segmentation Analysis

By Treatment Type:

  • Enzyme Replacement Therapy (ERT) dominates the market, accounting for 93.89% of the market in 2026, due to its established efficacy in treating lysosomal storage disorders.
  • Other treatments, including gene therapy and HSCT, are expected to grow at higher CAGR during the forecast period as more pipeline candidates advance through clinical trials.

By Disease Type:

  • MPS II (Hunter Syndrome) is projected to dominate with 24.25% market share in 2026, owing to key products like Elaprase and Hunterase.
  • Other types, including MPS I, IV A, VI, and VII (Sly syndrome), are expected to grow steadily, supported by newly approved therapeutics such as MEPSEVII (vestronidase alfa-vjbk).

By Route of Administration:

  • Intravenous (IV) administration dominates with 98.16% of revenue in 2026, as most approved therapies, including Elaprase, are delivered intravenously.
  • Intracerebroventricular (ICV) administration is limited but gaining attention with products like Hunterase.

By End-User:

  • Hospitals dominate the segment with 61.55% share in 2026, given the need for trained professionals to administer IV therapies safely.
  • Specialty clinics and other facilities are expanding in developed regions, driven by patient demand for specialized care.

Regional Analysis

North America: Market size of USD 2.06 billion in 2025, projected to reach USD 2.13 billion in 2026, driven by high awareness, reimbursement, and clinical trials.

Europe: Second-largest market with strong product presence; projected to grow at CAGR of 9.9%, with UK reaching USD 0.18 billion and Germany USD 0.27 billion by 2026.

Asia-Pacific: Expected fastest growth due to strong patient base and upcoming therapeutic launches; Japan market USD 333.9 million in 2025, projected to reach USD 0.37 billion in 2026, China market expected to reach USD 0.27 billion, and India USD 0.13 billion by 2026.

Rest of World: Latin America and Middle East & Africa are emerging markets, supported by growing healthcare infrastructure and government initiatives.

Competitive Landscape

The MPS treatment market is semi-consolidated, led by Shire (Takeda Pharmaceutical Company Limited) with Elaprase, and BioMarin with ALDURAZYME, VIMIZIM, and NAGLAZYME. Clinical-stage players like ArmaGen, REGENXBIO, Sangamo Therapeutics, and Denali Therapeutics are developing pipeline candidates to capture future market share. Key developments include FDA Fast Track designations for gene therapy candidates like LYS-SAF302 (Lysogene) and ABO-101 (Abeona Therapeutics).

Conclusion

The global mucopolysaccharidosis treatment market is projected to grow from USD 3.96 billion in 2025 to USD 9.74 billion by 2034, at a CAGR of 10.54%. Market growth is primarily driven by the unmet need for advanced therapeutics, increasing R&D investment in rare disease therapies, and emerging innovative treatments including gene therapy and stem cell interventions. While high costs and limited access in emerging countries remain challenges, expanding clinical pipelines, technological advancements, and increasing awareness are set to fuel sustainable growth in the MPS treatment market across all regions.

Segmentation By Treatment

  • Enzyme Replacement Therapy (ERT)
  • Others

By Disease Type

  • Mucopolysaccharidosis Type I
  • Mucopolysaccharidosis Type II
  • Mucopolysaccharidosis Type IV A
  • Mucopolysaccharidosis Type VI
  • Others

By Route of Administration

  • Intravenous
  • Intracerebroventricular (ICV)

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
  • Rest of the World

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Key Mucopolysaccharidosis Types - by key regions (2025)
  • 4.2. Pipeline Analysis
  • 4.3. Key Industry Developments
  • 4.4. Regulatory Scenario- by Key Regions
  • 4.5. Overview of Emerging Treatments for Mucopolysaccharidosis
  • 4.6. Reimbursement Scenario - by Key Regions

5. Global Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Treatment
    • 5.2.1. Enzyme Replacement Therapy (ERT)
    • 5.2.2. Others
  • 5.3. Market Analysis, Insights and Forecast - By Disease Type
    • 5.3.1. Mucopolysaccharidosis Type I
    • 5.3.2. Mucopolysaccharidosis Type II
    • 5.3.3. Mucopolysaccharidosis Type IV A
    • 5.3.4. Mucopolysaccharidosis Type VI
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.4.1. Intravenous
    • 5.4.2. Intracerebroventricular (ICV)
  • 5.5. Market Analysis, Insights and Forecast - By End User
    • 5.5.1. Hospitals
    • 5.5.2. Specialty Clinics
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia pacific
    • 5.6.4. Rest of the World

6. North America Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Treatment
    • 6.2.1. Enzyme Replacement Therapy (ERT)
    • 6.2.2. Others
  • 6.3. Market Analysis - By Disease Type
    • 6.3.1. Mucopolysaccharidosis Type I
    • 6.3.2. Mucopolysaccharidosis Type II
    • 6.3.3. Mucopolysaccharidosis Type IV A
    • 6.3.4. Mucopolysaccharidosis Type VI
    • 6.3.5. Others
  • 6.4. Market Analysis - By Route of Administration
    • 6.4.1. Intravenous
    • 6.4.2. Intracerebroventricular (ICV)
  • 6.5. Market Analysis - By End User
    • 6.5.1. Hospitals
    • 6.5.2. Specialty Clinics
    • 6.5.3. Others
  • 6.6. Market Analysis - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Treatment
    • 7.2.1. Enzyme Replacement Therapy (ERT)
    • 7.2.2. Others
  • 7.3. Market Analysis - By Disease Type
    • 7.3.1. Mucopolysaccharidosis Type I
    • 7.3.2. Mucopolysaccharidosis Type II
    • 7.3.3. Mucopolysaccharidosis Type IV A
    • 7.3.4. Mucopolysaccharidosis Type VI
    • 7.3.5. Others
  • 7.4. Market Analysis - By Route of Administration
    • 7.4.1. Intravenous
    • 7.4.2. Intracerebroventricular (ICV)
  • 7.5. Market Analysis - By End User
    • 7.5.1. Hospitals
    • 7.5.2. Specialty Clinics
    • 7.5.3. Others
  • 7.6. Market Analysis - By Country/ sub-region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Rest of Europe

8. Asia Pacific Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Treatment
    • 8.2.1. Enzyme Replacement Therapy (ERT)
    • 8.2.2. Others
  • 8.3. Market Analysis - By Disease Type
    • 8.3.1. Mucopolysaccharidosis Type I
    • 8.3.2. Mucopolysaccharidosis Type II
    • 8.3.3. Mucopolysaccharidosis Type IV A
    • 8.3.4. Mucopolysaccharidosis Type VI
    • 8.3.5. Others
  • 8.4. Market Analysis - By Route of Administration
    • 8.4.1. Intravenous
    • 8.4.2. Intracerebroventricular (ICV)
  • 8.5. Market Analysis - By End User
    • 8.5.1. Hospitals
    • 8.5.2. Specialty Clinics
    • 8.5.3. Others
  • 8.6. Market Analysis - By Country/ sub-region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Rest of Asia Pacific

9. Rest of the World Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Treatment
    • 9.2.1. Enzyme Replacement Therapy (ERT)
    • 9.2.2. Others
  • 9.3. Market Analysis - By Disease Type
    • 9.3.1. Mucopolysaccharidosis Type I
    • 9.3.2. Mucopolysaccharidosis Type II
    • 9.3.3. Mucopolysaccharidosis Type IV A
    • 9.3.4. Mucopolysaccharidosis Type VI
    • 9.3.5. Others
  • 9.4. Market Analysis - By Route of Administration
    • 9.4.1. Intravenous
    • 9.4.2. Intracerebroventricular (ICV)
  • 9.5. Market Analysis - By End User
    • 9.5.1. Hospitals
    • 9.5.2. Specialty Clinics
    • 9.5.3. Others

10. Competitive Analysis

  • 10.1. Key Industry Developments
  • 10.2. Global Market Share Analysis (2017)
  • 10.3. Competition Dashboard
  • 10.4. Comparative Analysis - Major Players
  • 10.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 10.5.1. Shire (Takeda Pharmaceutical Company Limited)
      • 10.5.1.1. Overview,
      • 10.5.1.2. Products & services,
      • 10.5.1.3. SWOT analysis,
      • 10.5.1.4. Recent developments,
      • 10.5.1.5. strategies,
      • 10.5.1.6. financials (based on availability)
    • 10.5.2. Denali Therapeutics
      • 10.5.2.1. Overview,
      • 10.5.2.2. Products & services,
      • 10.5.2.3. SWOT analysis,
      • 10.5.2.4. Recent developments,
      • 10.5.2.5. strategies,
      • 10.5.2.6. financials (based on availability)
    • 10.5.3. ArmaGen
      • 10.5.3.1. Overview,
      • 10.5.3.2. Products & services,
      • 10.5.3.3. SWOT analysis,
      • 10.5.3.4. Recent developments,
      • 10.5.3.5. strategies,
      • 10.5.3.6. financials (based on availability)
    • 10.5.4. REGENXBIO Inc.
      • 10.5.4.1. Overview,
      • 10.5.4.2. Products & services,
      • 10.5.4.3. SWOT analysis,
      • 10.5.4.4. Recent developments,
      • 10.5.4.5. strategies,
      • 10.5.4.6. financials (based on availability)
    • 10.5.5. Sangamo Therapeutics
      • 10.5.5.1. Overview,
      • 10.5.5.2. Products & services,
      • 10.5.5.3. SWOT analysis,
      • 10.5.5.4. Recent developments,
      • 10.5.5.5. strategies,
      • 10.5.5.6. financials (based on availability)
    • 10.5.6. BioMarin
      • 10.5.6.1. Overview,
      • 10.5.6.2. Products & services,
      • 10.5.6.3. SWOT analysis,
      • 10.5.6.4. Recent developments,
      • 10.5.6.5. strategies,
      • 10.5.6.6. financials (based on availability)
    • 10.5.7. Lysogene
      • 10.5.7.1. Overview,
      • 10.5.7.2. Products & services,
      • 10.5.7.3. SWOT analysis,
      • 10.5.7.4. Recent developments,
      • 10.5.7.5. strategies,
      • 10.5.7.6. financials (based on availability)
    • 10.5.8. Abeona Therapeutics Inc.
      • 10.5.8.1. Overview,
      • 10.5.8.2. Products & services,
      • 10.5.8.3. SWOT analysis,
      • 10.5.8.4. Recent developments,
      • 10.5.8.5. strategies,
      • 10.5.8.6. financials (based on availability)
    • 10.5.9. Ultragenyx Pharmaceutical
      • 10.5.9.1. Overview,
      • 10.5.9.2. Products & services,
      • 10.5.9.3. SWOT analysis,
      • 10.5.9.4. Recent developments,
      • 10.5.9.5. strategies,
      • 10.5.9.6. financials (based on availability)
    • 10.5.10. Genzyme Corporation
      • 10.5.10.1. Overview,
      • 10.5.10.2. Products & services,
      • 10.5.10.3. SWOT analysis,
      • 10.5.10.4. Recent developments,
      • 10.5.10.5. strategies,
      • 10.5.10.6. financials (based on availability)

11. Competitive Analysis

List of Tables

  • Table 1: Global Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 2: Global Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 3: Global Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
  • Table 5: Global Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 6: North America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 7: North America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 8: North America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
  • Table 10: North America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 11: Europe Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 12: Europe Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 13: Europe Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
  • Table 15: Europe Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 17: Asia Pacific Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 18: Asia Pacific Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
  • Table 20: Asia Pacific Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 22: Latin America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 23: Latin America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
  • Table 25: Latin America Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 27: Middle East & Africa Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 28: Middle East & Africa Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
  • Table 30: Middle East & Africa Mucopolysaccharidosis Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Mucopolysaccharidosis Treatment Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Mucopolysaccharidosis Treatment Market Value Share (%), by Treatment, 2025 & 2034
  • Figure 3: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Enzyme Replacement Therapy (ERT), 2021-2034
  • Figure 4: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 5: Global Mucopolysaccharidosis Treatment Market Value Share (%), by Disease Type, 2025 & 2034
  • Figure 6: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Mucopolysaccharidosis Type I, 2021-2034
  • Figure 7: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Mucopolysaccharidosis Type II, 2021-2034
  • Figure 8: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Mucopolysaccharidosis Type IV A, 2021-2034
  • Figure 9: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Mucopolysaccharidosis Type VI, 2021-2034
  • Figure 10: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 11: Global Mucopolysaccharidosis Treatment Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 12: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Intravenous, 2021-2034
  • Figure 13: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Intracerebroventricular (ICV), 2021-2034
  • Figure 14: Global Mucopolysaccharidosis Treatment Market Value Share (%), by End-user, 2025 & 2034
  • Figure 15: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Hospitals, 2021-2034
  • Figure 16: Global Mucopolysaccharidosis Treatment Market Forecast (US$ Mn), by Specialty Clinics, 2021-2034
  • Figure 17: Global Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 18: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 19: North America Mucopolysaccharidosis Treatment Market Value Share (%), by Treatment, 2025
  • Figure 20: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 21: North America Mucopolysaccharidosis Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 22: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
  • Figure 23: North America Mucopolysaccharidosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 24: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
  • Figure 25: North America Mucopolysaccharidosis Treatment Market Value Share (%), by End-user, 2025
  • Figure 26: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 27: North America Mucopolysaccharidosis Treatment Market Value Share (%), By Country, 2025
  • Figure 28: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 29: Europe Mucopolysaccharidosis Treatment Market Value Share (%), by Treatment, 2025
  • Figure 30: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 31: Europe Mucopolysaccharidosis Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 32: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
  • Figure 33: Europe Mucopolysaccharidosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
  • Figure 35: Europe Mucopolysaccharidosis Treatment Market Value Share (%), by End-user, 2025
  • Figure 36: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Europe Mucopolysaccharidosis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Asia Pacific Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 39: Asia Pacific Mucopolysaccharidosis Treatment Market Value Share (%), by Treatment, 2025
  • Figure 40: Asia Pacific Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 41: Asia Pacific Mucopolysaccharidosis Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 42: Asia Pacific Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
  • Figure 43: Asia Pacific Mucopolysaccharidosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 44: Asia Pacific Mucopolysaccharidosis Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
  • Figure 45: Asia Pacific Mucopolysaccharidosis Treatment Market Value Share (%), by End-user, 2025
  • Figure 46: Asia Pacific Mucopolysaccharidosis Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 47: Asia Pacific Mucopolysaccharidosis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 48: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 49: Latin America Mucopolysaccharidosis Treatment Market Value Share (%), by Treatment, 2025
  • Figure 50: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 51: Latin America Mucopolysaccharidosis Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 52: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
  • Figure 53: Latin America Mucopolysaccharidosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 54: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
  • Figure 55: Latin America Mucopolysaccharidosis Treatment Market Value Share (%), by End-user, 2025
  • Figure 56: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 57: Latin America Mucopolysaccharidosis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 58: Middle East & Africa Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 59: Middle East & Africa Mucopolysaccharidosis Treatment Market Value Share (%), by Treatment, 2025
  • Figure 60: Middle East & Africa Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 61: Middle East & Africa Mucopolysaccharidosis Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 62: Middle East & Africa Mucopolysaccharidosis Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
  • Figure 63: Middle East & Africa Mucopolysaccharidosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 64: Middle East & Africa Mucopolysaccharidosis Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
  • Figure 65: Middle East & Africa Mucopolysaccharidosis Treatment Market Value Share (%), by End-user, 2025
  • Figure 66: Middle East & Africa Mucopolysaccharidosis Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Mucopolysaccharidosis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Mucopolysaccharidosis Treatment Market Share (%), By Company, 2025